Debt-free Balance SheetZero reported debt and a SEK 75.8M equity base materially reduce solvency risk and give management flexibility to fund R&D or bridge to commercialization without immediate interest burdens. This balance-sheet strength supports operational continuity while the company pursues commercial traction.

Moderated Cash Burn ProfileOperating cash burn remains negative but has been described as not having 'exploded' versus prior years, implying controlled spending. A relatively steady cash-burn profile extends runway, allowing management to focus on key development and commercialization milestones rather than emergency financing.

Strategic Industry FocusNeola operates in diagnostic medical technology, a structurally resilient sector with persistent healthcare demand and long product lifecycles. Once regulatory and commercial hurdles are cleared, diagnostics can secure recurring institutional customers and stable long-term margins, supporting sustainable business economics.

Bears Say

No Commercial RevenueEffectively zero reported revenue over multiple years indicates a lack of commercial traction. Without product sales the company cannot self-fund operations, increasing dependence on external capital, delaying scaling, and elevating execution risk around achieving a durable revenue model.

Persistent Negative Operating Cash FlowConsistently negative operating cash flow and prior negative free cash flow show the core business consumes cash. Persistent outflows create ongoing financing dependency, raise dilution risk if equity is issued, and constrain the company's ability to invest sufficiently in sales, regulatory approval, or manufacturing scale-up.

Sustained Operating LossesSustained net losses with no clear inflection toward profitability reflect continued heavy investment without revenue offset. Ongoing losses erode equity over time, can force financing on unfavorable terms, and limit strategic flexibility if commercialization milestones are delayed.

Neola Medical AB News

Neola Medical’s Pivotal Study: A Game Changer in Neonatal Lung Monitoring?

Neola Medical AB (($SE:NEOLA)) announced an update on their ongoing clinical study. Study Overview: Neola Medical AB is...

4M ago

NEOLA

NEOLA FAQ

What was Neola Medical AB’s price range in the past 12 months?

Neola Medical AB lowest stock price was kr0.60 and its highest was kr3.04 in the past 12 months.

What is Neola Medical AB’s market cap?

Neola Medical AB’s market cap is kr67.50M.

When is Neola Medical AB’s upcoming earnings report date?

Neola Medical AB’s upcoming earnings report date is May 27, 2026 which is in 88 days.

How were Neola Medical AB’s earnings last quarter?

Neola Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.

Is Neola Medical AB overvalued?

According to Wall Street analysts Neola Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neola Medical AB pay dividends?

Neola Medical AB does not currently pay dividends.

What is Neola Medical AB’s EPS estimate?

Neola Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neola Medical AB have?

Neola Medical AB has 77,950,230 shares outstanding.

What happened to Neola Medical AB’s price movement after its last earnings report?

Neola Medical AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.267%.

Which hedge fund is a major shareholder of Neola Medical AB?

Currently, no hedge funds are holding shares in SE:NEOLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neola Medical AB

Neola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.